Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.
Las Vegas, Nevada, September 30, 2022 McapMediaWire Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing a unique drug to treat concussions, has decided to disband its athletic advisory board.
Sports advisory members have been strong advocates for concussion prevention and the importance of finding responsible treatments. We created the advisory board to increase awareness of our mission to provide much-needed pharmaceuticals for a condition that currently has no FDA-approved treatment. We recently completed a Phase I human trial where our drug was found to be safe and well tolerated. We are excited about the possibility of initiating a phase II trial to determine the efficacy and safety of the drug in concussion patients.
The press has misrepresented Odyssey Health, Inc. Odyssey has never directly or indirectly received any money from government or federal sources to fund drug development. Odyssey is not involved in any litigation. Odyssey Health, Inc. purchased the intellectual property and rights to the drug on March 1, 2021. The money to fund the development of the drug comes from accredited investors. The Company has contacted the press to inform them of the facts and inaccuracies.
In order to keep our focus, the company has decided to disband the Sports Advisory Board as it has distracted from our essential work in progress. Odyssey wants to continue to focus on this important drug candidate in hopes of providing much needed treatment. The Company will remain committed to bringing products to market that provide a solution to unmet medical needs.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Health Inc. (OTC: ODYY) is a medical company specializing in life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and develop distinct assets, intellectual property and exceptional technologies that deliver meaningful medical solutions. The Company focuses on areas that have identified technological advantage, offer superior clinical utility and have substantial market opportunity. For more information, visit the company’s website at www.odysseyhealthinc.com.
PRV-002 is a fully synthetic, non-natural neurosteroid being developed for the treatment of mTCL (concussion). In preclinical studies, PRV-002 demonstrated equivalent, if not superior, neuroprotective effects when compared to related neurosteroids. Animal models of concussion have demonstrated that PRV-002 reduces behavioral pathology associated with brain injury symptoms such as impaired memory, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress, and inflammation in the brain while restoring healthy blood circulation.
This press release may contain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on our current expectations and speak only as of the date hereof.
MCAP Media Feed | House